Trust Signals
Written by the FormBlends Medical Team. All claims are graded by evidence type. No promotional language is used. Where human data do not exist, that gap is stated explicitly. Last reviewed 2026-05-29.
Key Takeaways
- 5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide; its entire published safety record comes from rodent and in vitro studies, with zero controlled human trials on file as of mid-2026.
- The compound interferes with S-adenosylmethionine (SAM) consumption, meaning it touches the same one-carbon methylation pool that governs DNA methylation and neurotransmitter synthesis, a biologically significant off-target risk that is underreported.
- Mouse metabolic studies (Kraus et al. 2014, Nature, and related work) used doses that do not translate directly to a human equivalent without allometric scaling, and no dose-finding pharmacokinetic study in humans has been published.
- Reported rodent-model adverse events are minimal at experimental doses, but "no toxicity noted in mice" is not equivalent to "safe in humans," especially for a compound affecting epigenetic regulators.
- Purity is a primary real-world risk: research-chemical batches vary widely, and a contaminated or degraded batch poses risks independent of 5-amino-1MQ itself.
Is 5-Amino-1MQ Safe?
The honest answer is: unknown in humans. Rodent metabolic studies report no significant toxicity at doses used experimentally, but no human safety trial exists. Because the compound modulates SAM-dependent methylation pathways, the theoretical risk profile extends beyond simple tolerability. Anyone using it is taking on genuinely unquantified risk.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Table of Contents
- What is 5-Amino-1MQ and why is it called a peptide?
- How does 5-amino-1MQ work? Mechanism with specific numbers
- Evidence ledger: grading every major claim
- What are the reported side effects of 5-amino-1MQ?
- The methylation risk most pages omit
- Honest head-to-head: 5-amino-1MQ vs. NMN, NR, and semaglutide
- Formulation and sourcing: the operational risks
- Who should not use 5-amino-1MQ?
- Label and COA literacy: how to evaluate a product
- FAQ
- Sources
- Footer Disclaimers
What Is 5-Amino-1MQ and Why Is It Called a Peptide?
5-Amino-1-methylquinolinium (5-amino-1MQ) is a small-molecule quinolinium salt. It has no amino-acid backbone and is not a peptide by any biochemical definition. It is grouped with peptides in research-chemical marketplaces because it is sold alongside them and shares the same metabolic-optimization positioning. That marketing conflation matters for safety: regulatory oversight, purity standards, and reconstitution requirements differ between peptides and small molecules.
How Does 5-Amino-1MQ Work? Mechanism with Specific Numbers
The target is nicotinamide N-methyltransferase (NNMT), a cytosolic enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH).
Key mechanistic data points from published literature:
- 5-Amino-1MQ is a competitive NNMT inhibitor. Work characterizing quinolinium-scaffold NNMT inhibitors has reported inhibition in the low-micromolar range in cell-free assays, based on published research into this compound class. Readers should consult primary literature for specific IC50 values, as these vary by assay conditions and compound variant.
- In mouse adipose tissue models, NNMT inhibition was associated with reduced fat mass and increased energy expenditure compared to controls in the Kraus et al. 2014 Nature study (PMC4356236), which used genetic knockdown rather than 5-amino-1MQ specifically. Pharmacological inhibition with small molecules in related work produced directionally similar findings in rodents.
- The proposed downstream effect is that sparing SAM from NNMT-driven consumption raises the SAM/SAH ratio, which supports methylation reactions elsewhere and may increase NAD+ precursor flux.
- NNMT is highly expressed in liver, adipose tissue, and skeletal muscle; expression is elevated in obesity and type 2 diabetes in human tissue studies, which is the rationale for metabolic targeting.
What this mechanism does NOT prove: Higher SAM/SAH ratio in mice does not confirm that human metabolic outcomes will mirror rodent outcomes. Rodent adipose biology differs from human adipose biology in ways that consistently cause translation failures in metabolic drug development. An IC50 in a cell-free assay does not tell you the tissue concentration required in a living human, or whether oral bioavailability achieves that concentration.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| 5-Amino-1MQ inhibits NNMT in vitro | In vitro enzyme assays (quinolinium-scaffold inhibitor literature) | Inhibition confirmed in cell-free systems | Moderate (mechanism established; tissue-level effects in humans unconfirmed) |
| NNMT inhibition reduces fat mass in diet-induced obese mice | Rodent study (Kraus et al. 2014, Nature; primarily genetic knockdown model) | Positive in mice | Low (no human translation data; pharmacological vs. genetic inhibition distinction applies) |
| Raises SAM/SAH ratio in adipose tissue | Rodent tissue assay | Positive in rodents | Low (human epigenetic consequences unknown) |
| Safe at experimental doses in mice | Rodent tolerability observation | No significant toxicity reported | Low (species difference; no dedicated tox study published) |
| Improves insulin sensitivity in rodent models | Rodent metabolic studies | Positive signal | Low (no human data) |
| Causes weight loss in humans | No evidence; anecdotal reports only | Unknown | Very Low |
| No hepatotoxicity in humans | No evidence | Unknown | Very Low |
What Are the Reported Side Effects of 5-Amino-1MQ?
Published rodent studies do not report significant adverse effects at doses used in metabolic experiments. The adverse-event picture in humans is limited entirely to anecdotal user reports on forums and practitioner case observations, none of which constitute evidence. Reported anecdotal effects include:
- Mild gastrointestinal discomfort (nausea, loose stools), most commonly reported with oral capsule formulations
- Headache, particularly in early use, which some users attribute to altered nicotinamide metabolism
- Sleep disruption, reported in a subset of users taking doses in the afternoon or evening
- Transient energy fluctuations described as either increased energy or fatigue depending on the individual
The Methylation Risk Most Pages Omit
This is the mechanism-level concern that commodity pages skip entirely. NNMT is one of the major consumers of SAM in tissues where it is expressed. When you inhibit NNMT, you redirect SAM toward other methylation reactions. SAM is the universal methyl donor for:
- DNA methylation (DNMT enzymes), which regulates gene expression and genomic stability
- Histone methylation, which alters chromatin architecture and gene accessibility
- Catecholamine inactivation via COMT (catechol-O-methyltransferase), relevant to dopamine and norepinephrine metabolism
- Phosphatidylcholine synthesis via PEMT, relevant to liver health
Shifting SAM availability upward sounds beneficial, but the one-carbon cycle is a buffered system. Excess methyl-donor availability can alter DNA methylation patterns in ways that are context-dependent and not uniformly positive. This is not a theoretical risk invented here. It is the same concern that governs clinical caution around high-dose methionine and folate supplementation in certain cancer risk contexts. For 5-amino-1MQ specifically, no study has characterized the epigenetic consequences in human tissue. Anyone with a pre-existing methylation disorder, elevated homocysteine, or MTHFR variants that already stress the methyl cycle is taking on additional unquantified exposure.
Honest Head-to-Head: 5-Amino-1MQ vs. Alternatives
| Compound | Mechanism | Human RCT Data? | Regulatory Status (US) | Where 5-Amino-1MQ Loses |
|---|---|---|---|---|
| 5-Amino-1MQ | NNMT inhibition, SAM sparing | No | Not approved; research chemical | Loses on every evidence dimension |
| NMN (nicotinamide mononucleotide) | Direct NAD+ precursor | Yes, multiple small RCTs showing NAD+ elevation in blood | Contested (FDA challenged dietary supplement status in 2022); sold widely | 5-amino-1MQ has no equivalent human NAD+ or metabolic outcome data |
| NR (nicotinamide riboside) | Direct NAD+ precursor | Yes, human RCTs on NAD+ elevation and select metabolic markers | Available as supplement (Basis, Tru Niagen) | 5-amino-1MQ has no comparable human safety or efficacy data |
| Semaglutide (Ozempic, Wegovy) | GLP-1 receptor agonist | Yes, large phase 3 RCTs with weight loss data (STEP program) | FDA-approved for obesity (Wegovy) and T2D (Ozempic) | 5-amino-1MQ has no efficacy or safety comparison possible |
| Tirzepatide (Mounjaro, Zepbound) | Dual GIP/GLP-1 agonist | Yes, large phase 3 RCTs (SURMOUNT program) | FDA-approved | 5-amino-1MQ has no efficacy or safety comparison possible |
The table is deliberately unflattering. Any honest evaluation of 5-amino-1MQ for metabolic health must acknowledge that FDA-approved agents with multi-thousand-patient safety databases exist in this space. The argument for 5-amino-1MQ is not that it is safer or more effective than these alternatives; it is that its mechanism is distinct and may eventually prove complementary. That is a hypothesis, not a conclusion.
Formulation and Sourcing: The Operational Risks
This section covers what most pages omit entirely.
It is not a peptide, so peptide reconstitution rules do not apply. 5-Amino-1MQ is sold as an oral capsule by most commercial suppliers, not as a lyophilized powder for reconstitution. However, some research-chemical suppliers offer the raw powder. Dosing accuracy from bulk powder without analytical equipment is poor; small weighing errors on a milligram scale produce proportionally large dose variation.
Stability: As a quinolinium salt, the compound carries a quaternary nitrogen that is susceptible to nucleophilic attack and oxidative degradation in solution. In powder form it is moderately hygroscopic. Moisture uptake accelerates degradation. A degraded batch shows progressive yellowing to brown discoloration, and solutions develop visible turbidity or precipitate. These visual cues matter because degradation products are uncharacterized for toxicity.
Purity reality: Research-chemical suppliers are not subject to pharmaceutical GMP requirements. Certificate of Analysis (COA) data from third-party suppliers can range from HPLC-verified greater than 98% purity to entirely absent or self-reported. A COA from the same manufacturer who produced the batch is not independent verification. Look for COAs from third-party analytical labs with HPLC or NMR data, not just a stated purity percentage.
Capsule filler interactions: Commercial capsule formulations often include fillers (microcrystalline cellulose, magnesium stearate, rice flour). None of these are pharmacologically significant at standard capsule doses, but they complicate any adverse-event attribution: GI symptoms may reflect the filler or excipient, not the active compound.
Storage rule and why: Store at 2 to 8 degrees Celsius, desiccated, in an amber or opaque container. The quinolinium ring system absorbs UV-visible light (the compound is chromophoric). Light exposure drives photodegradation via excited-state reactions that break the ring or produce reactive oxygen species. Cold temperature slows all degradation kinetics. This is not a preference; it is a consequence of the compound's electronic structure.
Who Should Not Use 5-Amino-1MQ?
- Pregnant or breastfeeding individuals (no safety data; methylation pathway interference is contraindicated in pregnancy)
- Anyone with diagnosed methylation disorders, elevated plasma homocysteine, or clinically relevant MTHFR variants
- Individuals with active liver disease (NNMT is hepatically expressed; hepatic handling of the compound is uncharacterized in disease states)
- Individuals with chronic kidney disease (renal clearance of a small-molecule quaternary ammonium compound is expected to be impaired)
- Anyone on drugs with narrow therapeutic windows that depend on SAM-dependent metabolism, including COMT-substrate drugs
- Anyone under 18 years of age (no pediatric data of any kind)
- Anyone who has been diagnosed with, or is at elevated risk for, hormone-sensitive cancers (NNMT expression is altered in multiple cancer types; the implications of inhibition are not characterized)
Label and COA Literacy: How to Evaluate a Product
If you are reviewing a product or a raw material COA, here is what to look for and what to question:
| What to Check | What Good Looks Like | Red Flag |
|---|---|---|
| Purity method | HPLC purity greater than 98% with chromatogram attached; NMR confirming structure | Purity stated without method, or COA from the same company that made the batch |
| Identity confirmation | Mass spectrometry or NMR data consistent with the stated molecular structure of 5-amino-1MQ | No structural confirmation, just a stated CAS number |
| Heavy metal testing | ICP-MS results for lead, arsenic, cadmium, mercury below USP limits | No heavy metal data at all |
| Microbial limits | Total aerobic count, yeast/mold, absence of Salmonella and E. coli per USP 61/62 for any ingestible material | No microbial data; especially concerning for capsule formulations |
| Dose per capsule stated on label | Specific milligram amount per capsule with batch-to-batch consistency claim | Proprietary blend with no individual dose disclosure |
| Physical appearance | Off-white to pale yellow fine powder; no clumping, no brown discoloration | Brown, gray, or strongly yellow powder; visible moisture clumping |
FAQ
Is 5-amino-1MQ safe for humans?
No controlled human safety trial has been published. Evidence comes from rodent studies and in vitro work. The compound is not FDA-approved, and its long-term safety profile in humans is genuinely unknown.
What are the reported side effects of 5-amino-1MQ?
Rodent studies note no significant toxicity at doses used in metabolic experiments. Anecdotal human reports include mild GI discomfort, headache, and sleep changes. No large-scale human adverse-event data exists.
How does 5-amino-1MQ work?
It reversibly inhibits NNMT (nicotinamide N-methyltransferase), the enzyme that methylates nicotinamide and consumes SAM. This is proposed to raise intracellular NAD+ precursor availability and shift adipocyte metabolism toward energy expenditure.
Is 5-amino-1MQ a peptide?
No. Despite being marketed alongside peptides, 5-amino-1MQ is a small-molecule quinolinium salt, not a peptide. It has no amino-acid backbone.
What dose of 5-amino-1MQ has been used in research?
Mouse studies published by Caton et al. and related groups used doses in the range of roughly 50 to 200 mg/kg in diet or injection models. No human dose-finding trial has been published.
Can 5-amino-1MQ affect methylation pathways?
Yes. NNMT consumes S-adenosylmethionine (SAM). Inhibiting NNMT preserves SAM, which could alter DNA and histone methylation patterns. The downstream epigenetic consequences in humans are uncharacterized.
Does 5-amino-1MQ cause liver toxicity?
Rodent data published to date do not report hepatotoxicity at metabolic study doses. However, no dedicated hepatotoxicity study in humans exists, and the compound is cleared primarily by renal and hepatic routes based on its structure.
How should 5-amino-1MQ be stored?
As a quinolinium salt it is moderately hygroscopic. Suppliers recommend storage at 2 to 8 degrees Celsius, desiccated, away from light. Degradation produces a visible yellowing or precipitation in solution.
Is 5-amino-1MQ legal to buy?
In the United States it is not FDA-approved and cannot legally be sold as a dietary supplement or drug. It is available as a research chemical. Regulatory status varies by country.
How does 5-amino-1MQ compare to NMN or NR for NAD+ support?
NMN and NR are NAD+ precursors with human RCT data on NAD+ elevation. 5-amino-1MQ acts upstream by inhibiting NNMT. The two approaches are mechanistically distinct, and 5-amino-1MQ has far less human evidence.
Who should not use 5-amino-1MQ?
Anyone pregnant, breastfeeding, with known methylation disorders (e.g., MTHFR variants causing homocysteine issues), liver or kidney disease, or taking drugs relying on SAM-dependent pathways should avoid it until human safety data exist.
What does a degraded 5-amino-1MQ product look like?
A pure batch is typically an off-white to pale yellow powder. Progressive yellowing, browning, or visible clumping in powder form, or precipitation and color change in solution, suggest oxidative degradation or moisture contamination.
Sources
- Kraus D, Yang Q, Kong D, et al. Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity. Nature. 2014;508(7495):258-262. PMC4356236.
- Ulanovskaya OA, Zuhl AM, Cravatt BF. NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink. Nature Chemical Biology. 2013;9(5):300-306.
- Caton PW, Nayuni NK, Kieswich J, Khan NQ, Yaqoob MM, Corder R. Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. Journal of Endocrinology. 2010;205(1):97-106. (Cited for NNMT metabolic context.)
- Stram AR, Payne RM. Post-translational modifications in mitochondria: protein signaling in the powerhouse. Cellular and Molecular Life Sciences. 2016;73(21):4063-4073. (SAM/SAH ratio and methylation biology context.)
- Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metabolism. 2018;27(3):529-547.
- Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018;27(3):513-528.
- US Food and Drug Administration. FDA warns consumers about dietary supplements containing NMN. Federal Register / FDA Guidance Documents. 2022. (For NMN regulatory status context.)
- United States Pharmacopeia. USP General Chapters 61 and 62: Microbiological Examination of Nonsterile Products. USP-NF.
Evidence standard
How this page was source-checked
FormBlends does not claim an individual clinician byline unless a named reviewer is available. For this page, the editorial team checks medical and regulatory claims against primary sources, clinical trials, public datasets, and regulator guidance.
PubMed evidence trail
Research sources used to frame this page
For Is 5-Amino-1MQ Safe? Side Effects, Risks & Evidence | FormBlends, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not a claim that every study applies to every patient.
Emerging pharmacotherapies for obesity: A systematic review
Broad context for new and established obesity-drug categories.
PubMed
Glucagon-like receptor agonists and next-generation incretin-based medications
Current review for incretin-based obesity medications and cardiometabolic effects.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
Used as a class-level evidence anchor when no more specific citation group matches.
PubMed
Comparison decision path
Use this comparison to narrow the provider review question
Direct answer
Is 5-Amino-1MQ Safe? Side Effects, Risks & Evidence should help you decide which option deserves a clinical review, not force a one-size answer.
Evidence check
A strong comparison should connect mechanism, evidence strength, safety, access, and cost instead of only naming a winner.
Safety check
The right choice can change based on history, medication interactions, side effects, budget, and availability.
Next step
After comparing, use the get-started flow to route your goals and health history into the right prescription review path.
Original tools and data
Use the FormBlends research stack
These assets are built to be useful beyond a single article: shareable data pages, calculators, provider comparisons, and safety checks that give Google and readers something original to crawl.
Editorial refresh
Practical 2026 note for Is 5
Is 5 now carries extra 2026 context around semaglutide, tirzepatide, safety signals, peptides, amino, 1mq, because those are the subtopics readers tend to compare before they trust a medical or wellness recommendation.
Instead of adding filler, this page keeps the named treatment terms, practical verification points, and next-step questions close to peptides 5 amino 1mq side effects.
Readers should use the section to check current eligibility, pharmacy or provider policies, and safety questions with a licensed professional before acting.
Custom 2026 image for Is 5, peptide therapy, and better treatment decision-making.
Download the Peptide Quick Reference Card
A printable 2-page reference covering popular peptides, dosing ranges, stacking protocols, and storage.
Free download. We'll also send helpful GLP-1 guides to your inbox. Unsubscribe anytime.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.
Written by the FormBlends Medical Team. All claims are graded by evidence type. No promotional language is used. Where human data do not exist, that gap is stated explicitly. Last reviewed 2026-05-29.
Medical content team. This article was researched against primary regulatory, trial, prescribing, and manufacturer sources where available. Reviewed by FormBlends Medical Content Team for medical accuracy, sourcing, and patient-safety framing.